Phillips Angela K, Segovia Laura, Livinski Alicia A, Wilson Candy, Shet Arun S, Bevans Margaret
Operational Quality, Air Force Medical Agency, Falls Church, Virginia, USA.
College of Nursing, The Ohio State University, Columbus, Ohio, USA.
Womens Health Rep (New Rochelle). 2024 Dec 5;5(1):973-983. doi: 10.1089/whr.2024.0092. eCollection 2024.
Although there is an emerging body of evidence that addresses the adverse health outcomes of individuals with sickle cell trait (SCT), it is not clear if the findings are generalizable from a sex and gender perspective. The purpose of this scoping review was to complete an assessment of main concepts, identify knowledge gaps, and determine the potential value of conducting an eventual systematic review. The research question guiding this scoping review is: In SCT individuals with adverse health outcomes, what is known about sex and gender differences? We conducted a scoping review of research on SCT from 2016 to 2022 across five databases, with 36 research studies included in the review. The majority of the included studies were cohort studies (67%) in the United States (61%) focusing on a variety of health outcomes. One-third reported health outcomes by both SCT status and sex, and one-third controlled for sex; no studies addressed gender. Further research is needed on the role of sex and gender for individuals with SCT.
尽管有越来越多的证据表明镰状细胞性状(SCT)个体存在不良健康后果,但从性别角度来看,这些研究结果是否具有普遍性尚不清楚。本范围综述的目的是对主要概念进行评估,识别知识空白,并确定进行最终系统综述的潜在价值。指导本范围综述的研究问题是:在有不良健康后果的SCT个体中,关于性别差异我们了解多少?我们对2016年至2022年期间五个数据库中关于SCT的研究进行了范围综述,该综述纳入了36项研究。纳入的研究大多是队列研究(67%),在美国进行的占61%,关注各种健康结果。三分之一的研究报告了SCT状态和性别的健康结果,三分之一的研究控制了性别因素;没有研究涉及社会性别。对于SCT个体的性别和社会性别作用,还需要进一步研究。